BioVie (NASDAQ:BIVI) Trading Up 10.1% – Time to Buy?

Posted by Geri Gentry on Aug 11th, 2026

BioVie Inc. (NASDAQ:BIVI – Get Free Report) shares traded up 10.1% during mid-day trading on Monday . The stock traded as high as $1.1550 and last traded at $1.10. Approximately 1,246,162 shares changed hands during trading, an increase of 52% from the average session volume of 821,774 shares. The stock had previously closed at $0.9993.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BIVI. Wall Street Zen upgraded shares of BioVie to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings restated a “sell (e+)” rating on shares of BioVie in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on BioVie

BioVie Price Performance

The company has a market capitalization of $8.29 million, a PE ratio of -0.45 and a beta of 0.60. The business’s 50 day simple moving average is $1.71 and its 200 day simple moving average is $1.49.

BioVie (NASDAQ:BIVI – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.03.

Institutional Investors Weigh In On BioVie

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Prelude Capital Management LLC acquired a new position in shares of BioVie in the 3rd quarter valued at $275,000. Prosperity Wealth Management Inc. purchased a new stake in BioVie in the 3rd quarter valued at about $273,000. DRW Securities LLC purchased a new stake in BioVie in the 4th quarter valued at about $149,000. Citadel Advisors LLC purchased a new stake in BioVie in the 3rd quarter valued at about $199,000. Finally, Renaissance Technologies LLC lifted its position in BioVie by 142.4% in the first quarter. Renaissance Technologies LLC now owns 67,918 shares of the company’s stock valued at $95,000 after buying an additional 39,900 shares during the last quarter. Hedge funds and other institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

(Get Free Report)

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.